share_log

Jefferies Initiates Coverage On ImmunityBio with Buy Rating, Announces Price Target of $8

Benzinga Real-time News ·  Aug 3, 2022 07:18

Jefferies analyst Kelly Shi initiates coverage on ImmunityBio (NASDAQ:IBRX) with a Buy rating and announces Price Target of $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment